<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "5: Additional ", fill: "#5a4fcf"},
{source: "5: Additional ", target: "5: presently known", fill: "#5a4fcf"},
{source: "5: presently known", target: "5: immaterial may also impair", fill: "#5a4fcf"},
{source: "5: immaterial may also impair", target: "5: operations", fill: "#5a4fcf"},
{source: "5: Additional ", target: "7: technological", fill: "#228b22"},
{source: "7: technological", target: "7: frequent new product introductions", fill: "#228b22"},
{source: "7: technological", target: "9: successful new product introductions provide", fill: "#f77fbe"},
{source: "9: successful new product introductions provide", target: "9: significant", fill: "#f77fbe"},
{source: "9: significant", target: "9: competitive", fill: "#f77fbe"},
{source: "9: competitive", target: "9: investment", fill: "#f77fbe"},
{source: "9: investment", target: "9: use new products", fill: "#f77fbe"},
{source: "9: successful new product introductions provide", target: "10: competitors", fill: "#701c1c"},
{source: "10: competitors", target: "10: difficult", fill: "#701c1c"},
{source: "10: competitors", target: "19: companies may", fill: "#b57edc"},
{source: "19: companies may", target: "19: new technologies", fill: "#b57edc"},
{source: "19: new technologies", target: "19: compete with", fill: "#b57edc"},
{source: "19: compete with", target: "19: products obsolete", fill: "#b57edc"},
{source: "19: companies may", target: "20: Competition ", fill: "#e30b5d"},
{source: "20: Competition ", target: "20: reliability", fill: "#e30b5d"},
{source: "20: reliability", target: "20: introductions", fill: "#e30b5d"},
{source: "20: introductions", target: "20: proprietary", fill: "#e30b5d"},
{source: "20: proprietary", target: "20: technologies", fill: "#e30b5d"},
{source: "20: technologies", target: "20: distribution", fill: "#e30b5d"},
{source: "20: distribution", target: "20: capabilities", fill: "#e30b5d"},
{source: "20: capabilities", target: "20: of Contents ", fill: "#e30b5d"},
{source: "20: of Contents ", target: "20: technical support", fill: "#e30b5d"},
{source: "20: technical support", target: "20: product line", fill: "#e30b5d"},
{source: "20: Competition ", target: "21: competitor", fill: "#f5deb3"},
{source: "21: competitor", target: "21: technology", fill: "#f5deb3"},
{source: "21: technology", target: "21: costeffective", fill: "#f5deb3"},
{source: "21: costeffective", target: "21: alternatives", fill: "#f5deb3"},
{source: "21: alternatives", target: "21: operations", fill: "#f5deb3"},
{source: "21: operations", target: "21: materially", fill: "#f5deb3"},
{source: "21: materially", target: "21: adversely", fill: "#f5deb3"},
{source: "21: competitor", target: "29: prevented from selling", fill: "#cf0"},
{source: "29: prevented from selling", target: "29: license agreements", fill: "#cf0"},
{source: "29: prevented from selling", target: "30: Approximately ", fill: "#d71868"},
{source: "30: Approximately ", target: "30: product sales", fill: "#d71868"},
{source: "30: product sales", target: "30: attributable", fill: "#d71868"},
{source: "30: attributable", target: "30: products sold pursuant", fill: "#d71868"},
{source: "30: products sold pursuant", target: "30: license agreements", fill: "#d71868"},
{source: "30: Approximately ", target: "31: patented technology", fill: "#b5651d"},
{source: "31: patented technology", target: "31: may lose significant sources", fill: "#b5651d"},
{source: "31: patented technology", target: "51: licensor could lose patent", fill: "#7b68ee"},
{source: "51: licensor could lose patent", target: "51: invalidity", fill: "#7b68ee"},
{source: "51: invalidity", target: "51: unenforceability", fill: "#7b68ee"},
{source: "51: unenforceability", target: "51: licensed patent", fill: "#7b68ee"},
{source: "51: licensor could lose patent", target: "52: licensor against", fill: "#701c1c"},
{source: "52: licensor against", target: "52: third party", fill: "#701c1c"},
{source: "52: third party", target: "52: intellectual property infringement", fill: "#701c1c"},
{source: "52: licensor against", target: "61: founder chairman", fill: "#ffebcd"},
{source: "61: founder chairman", target: "61: directors chief executive officer", fill: "#ffebcd"},
{source: "61: directors chief executive officer", target: "61: president exerts", fill: "#ffebcd"},
{source: "61: president exerts", target: "61: control over", fill: "#ffebcd"},
{source: "61: founder chairman", target: "109: Therefore ", fill: "#7f00ff"},
{source: "109: Therefore ", target: "109: no assurances", fill: "#7f00ff"},
{source: "109: no assurances", target: "109: unauthorized use", fill: "#7f00ff"},
{source: "109: unauthorized use", target: "109: license limitations", fill: "#7f00ff"},
{source: "109: license limitations", target: "109: costeffective manner", fill: "#7f00ff"},
{source: "109: Therefore ", target: "114: arbitrations", fill: "#e52b50"},
{source: "114: arbitrations", target: "114: legal actions particularly involving", fill: "#e52b50"},
{source: "114: legal actions particularly involving", target: "114: infringement", fill: "#e52b50"},
{source: "114: infringement", target: "114: intellectual property rights", fill: "#e52b50"},
{source: "114: arbitrations", target: "123: intellectual", fill: "#a67b5b"},
{source: "123: intellectual", target: "123: litigation", fill: "#a67b5b"},
{source: "123: litigation", target: "123: affecting", fill: "#a67b5b"},
{source: "123: intellectual", target: "125: litigations described", fill: "#fada5e"},
{source: "125: litigations described", target: "125: following paragraphs", fill: "#fada5e"},
{source: "125: following paragraphs", target: "125: adversely could", fill: "#fada5e"},
{source: "125: litigations described", target: "START_HERE", fill: "#fada5e"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Life Sciences Tools and Services</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Promise policy support</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Statistical_significance">Statistical significance</a></td>
      <td>In statistical hypothesis testing, a result has statistical significance when it is very unlikely to have occurred given the null hypothesis. More precisely, a study's defined significance level, denoted by \n  \n    \n      \n        α\n      \n    \n    {\displaystyle \alpha }\n  , is the probability of the study rejecting the null hypothesis, given that the null hypothesis is true; and the p-value of a result, \n  \n    \n      \n        p\n      \n    \n    {\displaystyle p}\n  , is the probability of obtaining a result at least as extreme, given that the null hypothesis is true.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitive_programming">Competitive programming</a></td>
      <td>Competitive programming is a mind sport usually held over the Internet or a local network, involving participants trying to program according to provided specifications. Contestants are referred to as sport programmers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitive_inhibition">Competitive inhibition</a></td>
      <td>Competitive inhibition is interruption of a chemical pathway owing to one chemical substance inhibiting the effect of another by competing with it for binding or bonding. Any metabolic or chemical messenger system can potentially be affected by this principle, but several classes of competitive inhibition are especially important in biochemistry and medicine, including the competitive form of enzyme inhibition, the competitive form of receptor antagonism, the competitive form of antimetabolite activity, and the competitive form of poisoning (which can include any of the aforementioned types).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Esports">Esports</a></td>
      <td>Sport pertains to any form of competitive physical activity or game that aims to use, maintain, or improve physical ability and skills while providing enjoyment to participants and, in some cases, entertainment to spectators. Sports can, through casual or organized participation, improve one's physical health.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_analysis">Competitor analysis</a></td>
      <td>Competitive analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors. This analysis provides both an offensive and defensive strategic context to identify opportunities and threats.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sport_of_athletics">Sport of athletics</a></td>
      <td>Athletics is a group of sporting events that involves competitive running, jumping, throwing, and walking. The most common types of athletics competitions are track and field, road running, cross country running, and racewalking.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_female_fitness_and_figure_competitors">List of female fitness and figure competitors</a></td>
      <td>This is a list of female fitness and figure competitors.\n\n\n== A ==\nJelena Abbou\n\n\n== B ==\nLauren Beckham\nAlexandra Béres\nSharon Bruneau\n\n\n== C ==\nNatalie Montgomery-Carroll\nJen Cassetty\nKim Chizevsky\nSusie Curry\n\n\n== D ==\nDebbie Dobbins\nNicole Duncan\n\n\n== E ==\nJamie Eason\nAlexis Ellis\n\n\n== F ==\nAmy Fadhli\nJaime Franklin\n\n\n== G ==\nAdela García \nConnie Garner\nElaine Goodlad\nTracey Greenwood\nOksana Grishina\n\n\n== H ==\nMallory Haldeman\nVanda Hădărean\nJen Hendershott\nSoleivi Hernandez\nApril Hunter\n\n\n== I ==\n\n\n== J ==\nTsianina Joelson\n\n\n== K ==\nAdria Montgomery-Klein\nAshley Kaltwasser\n\n\n== L ==\nLauren Lillo\nMary Elizabeth Lado\nTammie Leady\nJennifer Nicole Lee\nAmber Littlejohn\nJulie Lohre\nJenny Lynn\n\n\n== M ==\nTimea Majorová\nLinda Maxwell\nDavana Medina\nJodi Leigh Miller\nChisato Mishima\n\n\n== N ==\nKim Nielsen\n\n\n== O ==\n\n\n== P ==\nVicky Pratt\nElena Panova\nChristine Pomponio-Pate\nCathy Priest\n\n\n== Q ==\n\n\n== R ==\nMaite Richert\nCharlene Rink\nKelly Ryan\n\n\n== S ==\nErin Stern\nCarol Semple-Marzetta\nKrisztina Sereny\nTrish Stratus (Patricia Anne Stratigias)\n\n\n== T ==\nKristi Tauti\nJennifer Thomas\n\n\n== U ==\n\n\n== V ==\nLisa Marie Varon\n\n\n== W ==\nLatisha Wilder\nTorrie Wilson\nLyen Wong\nJenny Worth\nNicole Wilkins\n\n\n== Y ==\n\n\n== Z ==\nMarietta Žigalová\nMalika Zitouni\n\n\n== See also ==\nList of female bodybuilders\n\n\n== References ==\nThere has been a rise in the number of women wanting to compete as fitness models.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_Group">Competitor Group</a></td>
      <td>Competitor Group, Inc. (CGI) is a privately held, for-profit, sports marketing and management company based in Mira Mesa, San Diego, California.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emerging_technologies">Emerging technologies</a></td>
      <td>Emerging technologies are technologies whose development, practical applications, or both are still largely unrealized, such that they are figuratively emerging into prominence from a background of nonexistence or obscurity. These technologies are generally new but also include older technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Space_technology">Space technology</a></td>
      <td>Space technology is technology for use in outer space, in travel (astronautics) or other activities beyond Earth's atmosphere, for purposes such as spaceflight, space exploration, and Earth observation. Space technology includes space vehicles such as spacecraft, satellites, space stations and orbital launch vehicles; deep-space communication; in-space propulsion; and a wide variety of other technologies including support infrastructure equipment, and procedures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renaissance_Technologies">Renaissance Technologies</a></td>
      <td>Renaissance Technologies LLC, also known as RenTech or RenTec, is an American hedge fund based in East Setauket, New York, on Long Island, which specializes in systematic trading using quantitative models derived from mathematical and statistical analysis. Their signature Medallion fund is famed for the best record in investing history.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Palantir_Technologies">Palantir Technologies</a></td>
      <td>Palantir Technologies is a public American software company that specializes in big data analytics. Headquartered in Denver, Colorado, it was founded by Peter Thiel, Nathan Gettings, Joe Lonsdale, Stephen Cohen, and Alex Karp in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_Technologies">United Technologies</a></td>
      <td>United Technologies Corporation (UTC) was an American multinational conglomerate headquartered in Farmington, Connecticut.  It researched, developed, and manufactured products in numerous areas, including aircraft engines, aerospace systems, HVAC, elevators and escalators, fire and security, building automation, and industrial products, among others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Current_Contents">Current Contents</a></td>
      <td>Current Contents is a rapid alerting service database from Clarivate Analytics, formerly the Institute for Scientific Information and Thomson Reuters. It is published online and in several different printed subject sections.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Victory_Contents">Victory Contents</a></td>
      <td>Victory Contents (Korean: 빅토리콘텐츠; RR: bigtoli kontencheu) is a Korean drama production company based in Seoul.\n\n\n== History ==\nsource: \n\nApril 4, 2003 - Music Encyclopedia was established.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_technology">Financial technology</a></td>
      <td>Financial technology (abbreviated fintech or FinTech) is the technology and innovation that aims to compete with traditional financial methods in the delivery of financial services. Artificial intelligence, Blockchain, Cloud computing, and big Data are regarded as the "ABCD" (four key areas) of FinTech.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Educational_technology">Educational technology</a></td>
      <td>Educational technology (commonly abbreviated as edutech, or edtech) is the combined use of computer hardware, software, and educational theory and practice to facilitate learning. When referred to with its abbreviation, edtech, it is often referring to the industry of companies that create educational technology.In addition to practical educational experience, educational technology is based on theoretical knowledge from various disciplines such as communication, education, psychology, sociology, artificial intelligence, and computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/License">License</a></td>
      <td>A license (or licence in British English) is an official permission or permit to do, use, or own something (as well as the document of that permission or permit).A license is granted by a party (licensor) to another party (licensee) as an element of an agreement between those parties. In the case of a license issued by a government, the license is obtained by applying for it.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_license">Software license</a></td>
      <td>A software license is a legal instrument (usually by way of contract law, with or without printed material) governing the use or redistribution of software. Under United States copyright law, all software is copyright protected, in both source code and object code forms, unless that software was developed by the United States Government, in which case it cannot be copyrighted.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Copyright_infringement">Copyright infringement</a></td>
      <td>Copyright infringement (at times referred to as piracy) is the use of works protected by copyright without permission for a usage where such permission is required, thereby infringing certain exclusive rights granted to the copyright holder, such as the right to reproduce, distribute, display or perform the protected work, or to make derivative works. The copyright holder is typically the work's creator, or a publisher or other business to whom copyright has been assigned.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Patent">Patent</a></td>
      <td>A patient is any recipient of health care services that are performed by healthcare professionals. The patient is most often ill or injured and in need of treatment by a physician, nurse, optometrist, dentist, veterinarian, or other health care provider.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Trademark">Trademark</a></td>
      <td>A trademark (also written trade mark or trade-mark) is a type of intellectual property consisting of a recognizable sign, design, or expression that identifies products or services from a particular source and distinguishes them from others. The trademark owner can be an individual, business organization, or any legal entity.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectual_property">Intellectual property</a></td>
      <td>Intellectual property (IP) is a category of property that includes intangible creations of the human intellect. There are many types of intellectual property, and some countries recognize more than others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Design_infringement">Design infringement</a></td>
      <td>Design is a form of intellectual property right concerned with the visual appearance of articles which have commercial or industrial use. The visual form of the product is what is protected rather than the product itself.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Chief_executive_officer">Chief executive officer</a></td>
      <td>A chief executive officer (CEO), chief administrator officer (CAO), central executive officer (CEO), or just chief executive (CE), is one of a number of corporate executives charged with the management of an organization –  especially an independent legal entity such as a company or nonprofit institution. CEOs find roles in a range of organizations, including public and private corporations, non-profit organizations and even some government organizations (notably state-owned enterprises).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Fair_use">Fair use</a></td>
      <td>Fair use is a doctrine in United States law that permits limited use of copyrighted material without having to first acquire permission from the copyright holder. Fair use is one of the limitations to copyright intended to balance the interests of copyright holders with the public interest in the wider distribution and use of creative works by allowing as a defense to copyright infringement claims certain limited uses that might otherwise be considered infringement.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Copyright_law_of_the_United_States">Copyright law of the United States</a></td>
      <td>The Copyright Law of the United States grants monopoly protection for "original works of authorship". With the stated purpose to promote art and culture, copyright law assigns a set of exclusive rights to authors: to make and sell copies of their works, to create derivative works, and to perform or display their works publicly.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Vexatious_litigation">Vexatious litigation</a></td>
      <td>Vexatious litigation is legal action which is brought  solely to harass or subdue an adversary. It may take the form of a primary frivolous lawsuit or may be the repetitive, burdensome, and unwarranted filing of meritless motions in a matter which is otherwise a meritorious cause of action.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/International_litigation">International litigation</a></td>
      <td>International litigation, sometimes called transnational litigation, is the practice of litigation in connection with disputes among businesses or individuals residing or based in different countries.\nThe main difference between international litigation and domestic litigation is that, in the former, certain issues are more likely to be of significance — such as personal jurisdiction, service of process, evidence from abroad, and enforcement of judgments.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Litigation_strategy">Litigation strategy</a></td>
      <td>Litigation strategy is the process by which counsel for one party to a lawsuit intends to integrate their actions with anticipated events and reactions to achieve the overarching goal of the litigation.  The strategic goal may be the verdict, or the damages or sentence awarded in the case.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>STRATAGENE CORP      Item 1A     Risk Factors             It is important to <font color="blue">carefully</font> consider the <font color="blue">following risks</font>, together     with  other  <font color="blue">matters described</font> in this Form 10-K or in other <font color="blue">documents</font>     referred to in this Form 10-K in evaluating our business and prospects</td>
    </tr>
    <tr>
      <td>If     any of the <font color="blue">following risks</font> occur, our business, <font color="blue">financial condition</font> or     operating results could be harmed</td>
    </tr>
    <tr>
      <td>In such case, the <font color="blue">trading price</font> of our     <font color="blue"><font color="blue">common stock</font> could decline</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">risks described</font> below are not the only risks     we face</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>risks not <font color="blue">presently known</font> to us or that we currently     deem <font color="blue">immaterial may also impair</font> business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">future <font color="blue">success depends</font> on</font> the <font color="blue">timely introduction</font> of <font color="blue">new products</font> and     the <font color="blue">acceptance</font> of these <font color="blue">new products</font> in the marketplace</td>
    </tr>
    <tr>
      <td>Rapid <font color="blue">technological</font> change and <font color="blue">frequent new product <font color="blue">introductions</font></font> are     typical for the markets we serve</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future success will depend</font> in large     part <font color="blue">on continuing</font> to develop and introduce <font color="blue">new products</font> in a <font color="blue">timely manner</font>     that <font color="blue">address evolving market <font color="blue">requirements</font></font></td>
    </tr>
    <tr>
      <td>We believe <font color="blue">successful new product <font color="blue">introductions</font> provide</font> a <font color="blue">significant</font>     <font color="blue">competitive</font>  advantage because customers make an <font color="blue">investment</font> of time in     selecting and learning to use <font color="blue">new products</font> and are reluctant to switch     thereafter</td>
    </tr>
    <tr>
      <td>To the extent that we fail to introduce new and innovative     products,  we  may  lose market share to our <font color="blue"><font color="blue">competitor</font>s</font>, which may be     <font color="blue">difficult</font> to regain</td>
    </tr>
    <tr>
      <td>Any <font color="blue">inability</font>, for <font color="blue">technological</font> or other reasons, to     <font color="blue">successfully</font> develop and introduce <font color="blue">new products</font> could <font color="blue">materially</font> damage our     business</td>
    </tr>
    <tr>
      <td>In the past we have experienced, and are likely to experience in the     future, delays in developing and <font color="blue">introducing products</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you     that we will keep pace with the rapid rate of change in <font color="blue">life sciences</font> or     <font color="blue">clinical <font color="blue">diagnostic</font> research</font>, or that our <font color="blue">new products</font> will adequately meet     the <font color="blue">requirements</font> of the marketplace or achieve market <font color="blue">acceptance</font></td>
    </tr>
    <tr>
      <td>Some of     the factors <font color="blue">affecting</font> market <font color="blue">acceptance</font> of <font color="blue">new products</font> include:         •  <font color="blue">availability</font>, quality and price relative to <font color="blue">competitive</font> products;         •  the timing of introducing the product relative to <font color="blue">competitive</font> products;         •  customers’ opinions of the product’s utility;         •  citation of the product in <font color="blue">published research</font>; and         •  <font color="blue">general trends</font> in <font color="blue">life sciences</font> and <font color="blue">clinical <font color="blue">diagnostic</font>s research</font></td>
    </tr>
    <tr>
      <td>The markets for our products are extremely <font color="blue">competitive</font> and subject to rapid     <font color="blue">technological</font> change and if we fail to <font color="blue">compete <font color="blue">effectively</font></font>, our business may     suffer</td>
    </tr>
    <tr>
      <td>The markets for our products are highly <font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">compete with</font>     many  other  suppliers of <font color="blue">life sciences</font> research products and clinical     <font color="blue">diagnostic</font>  products</td>
    </tr>
    <tr>
      <td>Many of our <font color="blue"><font color="blue">competitor</font>s</font> have greater financial,     operational  and  sales and marketing resources and more experience in     research and <font color="blue">development</font> than we do</td>
    </tr>
    <tr>
      <td>These and other <font color="blue">companies may</font> have     developed or could in the future develop <font color="blue">new <font color="blue">technologies</font></font> that <font color="blue">compete with</font>     our  products or even render our <font color="blue">products obsolete</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>in our     markets is primarily driven by:         •  product performance, features and <font color="blue">reliability</font>;         •  price;         •  timing of product <font color="blue">introductions</font>;         •  ability to develop, maintain and protect <font color="blue">proprietary</font> products and     <font color="blue">technologies</font>;         •  sales and <font color="blue">distribution</font> <font color="blue">capabilities</font>;                                         8       _________________________________________________________________    [62]Table of <font color="blue">Contents       </font>  •  <font color="blue">technical support</font> and service; and         •  breadth of <font color="blue">product line</font></td>
    </tr>
    <tr>
      <td>If  a  <font color="blue">competitor</font>  develops  or acquires superior <font color="blue">technology</font> or     cost-effective  <font color="blue">alternatives</font>  to our products, our business, financial     condition and results of <font color="blue">operations</font> could be <font color="blue">materially</font> <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">competitor</font>s</font> have in the past and may in the <font color="blue">future compete by</font>     <font color="blue">lowering prices</font></td>
    </tr>
    <tr>
      <td>We may respond by lowering our prices, which could reduce     revenues and profits</td>
    </tr>
    <tr>
      <td>Conversely, failure to anticipate and respond to price     <font color="blue"><font color="blue">competition</font> may damage</font> our market share</td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">must continually</font>     adapt  to  new  marketing  and <font color="blue">distribution</font> trends in order to compete     <font color="blue">effectively</font></td>
    </tr>
    <tr>
      <td>We believe that customers in our <font color="blue">markets display</font> a <font color="blue">significant</font> amount     of loyalty to their <font color="blue">initial supplier</font> of a <font color="blue">particular product</font></td>
    </tr>
    <tr>
      <td>Therefore, it     may be <font color="blue">difficult</font> to make sales to customers who have <font color="blue">previously purchased</font>     <font color="blue">products from</font> our <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td>To the extent we are unable to be the first     to develop and supply <font color="blue">new products</font>, our <font color="blue">competitive</font> position may suffer</td>
    </tr>
    <tr>
      <td>We may be <font color="blue">prevented from selling</font> some of our products if our existing     <font color="blue">license <font color="blue">agreement</font>s</font> are terminated</td>
    </tr>
    <tr>
      <td><font color="blue">Approximately </font>51prca of our <font color="blue">product sales</font> in 2005 were <font color="blue">attributable</font> to     <font color="blue">products sold pursuant</font> to <font color="blue">license <font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>If we lose the rights to use a     patented <font color="blue">technology</font>, we may be forced to stop selling some of our products     or redesign our products and may lose <font color="blue">significant</font> sources of revenues</td>
    </tr>
    <tr>
      <td>Losing a <font color="blue">significant</font> <font color="blue">license could</font> have a material adverse effect     on our business</td>
    </tr>
    <tr>
      <td>Our <font color="blue">significant</font> licenses include:         •  a <font color="blue">license from</font> <font color="blue">Applera Corporation </font>(<font color="blue">which license</font> was assigned to     Applera from Hoffman La Roche and Roche Molecular Systems, Inc</td>
    </tr>
    <tr>
      <td>in 2005)     granting us, among other rights, the right to <font color="blue">manufacture</font>, promote and sell     <font color="blue">certain products</font> for use in the research field in a process referred to as     the “PCR process;” and          •   a  license  from  Applied Biosystems, <font color="blue">which grants us rights</font> to     <font color="blue">manufacture</font>,  promote  and  sell  thermal  cyclers (certain laboratory     <font color="blue">instruments capable</font> of <font color="blue">generating</font> and maintaining <font color="blue">specific temperatures</font> for     a <font color="blue">defined period</font> of time) <font color="blue">under certain patents</font> for use in the research     field</td>
    </tr>
    <tr>
      <td>Applera <font color="blue">may terminate</font> its license <font color="blue">agreement</font> (1) for cause, (2) if     <font color="blue">certain parties</font> acquire more than 50prca of the <font color="blue">voting stock</font> of our subsidiary     that is a party to the <font color="blue">agreement</font>, and (3) in the event of our <font color="blue">bankruptcy</font> or     <font color="blue">insolvency</font></td>
    </tr>
    <tr>
      <td>Since mid-2003 and through late 2005, we <font color="blue">withheld royalty</font>     payments to Applera under this license <font color="blue">agreement</font> pending further evaluation     of a <font color="blue">potential <font color="blue">overpayment</font></font> of <font color="blue">royalties paid</font> to Applera in <font color="blue">prior periods</font></td>
    </tr>
    <tr>
      <td>During that period, we continued to record estimated <font color="blue">quarterly royalties</font>     <font color="blue">payable under</font> this license <font color="blue">agreement</font> and report these amounts to Applera</td>
    </tr>
    <tr>
      <td>We     believe  that  we  determine  the royalties we calculate and accrue in     <font color="blue">accordance with</font> the terms of this patent license <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>However, our     royalty  <font color="blue">calculations</font>  are subject to review by Applera</td>
    </tr>
    <tr>
      <td>Our financial     position  or results of <font color="blue">operations</font> could be <font color="blue">materially</font> affected if the     parties determine that the royalties differ <font color="blue">significant</font>ly from the amounts     we have recorded</td>
    </tr>
    <tr>
      <td>Additionally, there can be <font color="blue">no assurances</font> that we will     recover any <font color="blue">overpayment</font> in <font color="blue">royalties paid</font> in <font color="blue">prior periods</font></td>
    </tr>
    <tr>
      <td>The US patents     that covered the PCR <font color="blue">process underlying</font> this <font color="blue">royalty obligation expired</font> in     March 2005</td>
    </tr>
    <tr>
      <td>The <font color="blue">corresponding foreign patents will</font> expire in 2006 and 2007</td>
    </tr>
    <tr>
      <td>Upon expiration of these <font color="blue">patents outside</font> of the United States, we will no     longer be required to <font color="blue">pay royalties under</font> these <font color="blue">patents on future product</font>     sales</td>
    </tr>
    <tr>
      <td>The <font color="blue">agreement</font> with <font color="blue">Applied Biosystems </font>may be terminated (1) for cause,     (2) upon the change in control of our subsidiary that is a party to the     license <font color="blue">agreement</font>, and (3) in the event of our <font color="blue">bankruptcy</font> or <font color="blue">insolvency</font></td>
    </tr>
    <tr>
      <td>We  do  not anticipate that either of these <font color="blue">significant</font> license     <font color="blue">agreement</font>s will terminate in the near future</td>
    </tr>
    <tr>
      <td>Our <font color="blue">licenses typically</font> subject us to <font color="blue">various commercialization</font>,     <font color="blue">sublicensing</font> and other material <font color="blue">obligations</font></td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">comply with</font> these     <font color="blue">requirements</font>, we <font color="blue">could lose important <font color="blue">rights under</font></font> a license, such as the                                         9       _________________________________________________________________    [63]Table of <font color="blue">Contents       </font>right to <font color="blue">exclusivity</font> in a <font color="blue">specified market</font></td>
    </tr>
    <tr>
      <td>In some cases, we <font color="blue">could also</font>     lose all <font color="blue">rights under</font> a license</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">licensor could lose patent</font>     protection  for  a  number  of  reasons,  including  the <font color="blue">invalidity</font> or     <font color="blue">unenforceability</font>  of  the <font color="blue">licensed patent</font></td>
    </tr>
    <tr>
      <td>We typically do not receive     <font color="blue">significant</font> indemnification under such arrangements from a <font color="blue">licensor against</font>     <font color="blue">third party</font> claims of <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> <font color="blue">infringement</font></font></td>
    </tr>
    <tr>
      <td>Because our <font color="blue">quarterly revenue</font> and operating results may vary <font color="blue">significant</font>ly     in <font color="blue">future periods</font>, our <font color="blue">stock price may decline</font></td>
    </tr>
    <tr>
      <td>Our operating results have fluctuated in the past and <font color="blue">may continue</font> to     fluctuate in the future</td>
    </tr>
    <tr>
      <td>In particular, we have <font color="blue"><font color="blue">historically</font> seen slower</font>     sales in the <font color="blue">fourth quarter as</font> a result of <font color="blue">reduced purchases by academic</font> and     <font color="blue">research institutions as well as</font> the closing of <font color="blue">such facilities during</font> the     <font color="blue">holiday period</font></td>
    </tr>
    <tr>
      <td>Our revenues are unpredictable and <font color="blue">may also fluctuate due</font> to     changes in demand for our products, delays in developing and <font color="blue">introducing new</font>     products and new product <font color="blue">introductions</font> by our <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">high proportion</font>     of our costs are fixed, due in part to <font color="blue">significant</font> research and <font color="blue">development</font>     costs</td>
    </tr>
    <tr>
      <td>Thus, small declines in <font color="blue">revenue could disproportionately affect</font>     operating  results  in a quarter and the price of our <font color="blue"><font color="blue">common stock</font> may</font>     decline</td>
    </tr>
    <tr>
      <td>Because of these     factors, our operating results in one or more future quarters may fail to     meet the <font color="blue">expectations</font> of securities analysts or investors, which <font color="blue">could also</font>     cause our stock price to decline</td>
    </tr>
    <tr>
      <td>Our founder, chairman of our board of <font color="blue">directors</font>, <font color="blue">chief executive officer</font> and     <font color="blue">president exerts</font> considerable <font color="blue">control over</font> our business</td>
    </tr>
    <tr>
      <td><font color="blue">As of <font color="blue">December </font></font>31, 2005, Joseph A Sorge, MD, our founder, chairman     of  the  board  of  <font color="blue">directors</font>,  <font color="blue">chief executive officer</font> and president,     <font color="blue">beneficially</font> owned approximately 60prca of our <font color="blue">outstanding <font color="blue">common stock</font></font></td>
    </tr>
    <tr>
      <td>Sorge  controls  all  matters  requiring  approval of our     <font color="blue">stockholders</font>, including electing <font color="blue">directors</font> and <font color="blue">approving mergers</font> or other     business <font color="blue">combinations</font></td>
    </tr>
    <tr>
      <td>Such a <font color="blue">concentration</font> of ownership may have the effect     of delaying or preventing <font color="blue">transactions</font> resulting in our change of control,     including <font color="blue">transactions</font> where <font color="blue">stockholders</font> might otherwise receive a premium     for their shares over then current market prices</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend substantially on <font color="blue">key employees</font></font>, and losing the services of any of     our <font color="blue">key employees</font> or failing to <font color="blue">hire qualified employees could seriously</font>     damage our business</td>
    </tr>
    <tr>
      <td>To a large degree, we depend on our founder, chairman of our board of     <font color="blue">directors</font>, <font color="blue">chief executive officer</font> and president, Joseph A Sorge, MD Dr</td>
    </tr>
    <tr>
      <td>Sorge has <font color="blue">significant</font> expertise in the <font color="blue">life sciences</font> research market and has     <font color="blue">been instrumental</font> in <font color="blue">establishing</font> and executing our business plan</td>
    </tr>
    <tr>
      <td>Sorge’s <font color="blue">services could</font> have a material adverse effect on our business</td>
    </tr>
    <tr>
      <td>Sorge has an existing <font color="blue">employment</font> <font color="blue">agreement</font> with us, which expires in     June  2007, subject to <font color="blue">automatic one year renewals unless either party</font>     <font color="blue">provides timely</font> notice of non-renewal</td>
    </tr>
    <tr>
      <td>We maintain <font color="blue">directors</font> and officers     insurance for the benefit of our officers and <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>Because our products and services are <font color="blue">highly technical</font> in nature, only     <font color="blue">highly qualified</font> and <font color="blue">trained scientists</font> have the <font color="blue"><font color="blue">necessary</font> skills</font> to develop     and  market our products and provide our services</td>
    </tr>
    <tr>
      <td>As such, our future     <font color="blue">success also will depend</font> in large part on the <font color="blue">continued service</font> of our key     scientific and <font color="blue">management personnel</font>, including research and <font color="blue">development</font>,     customer service, marketing and <font color="blue">sales staffs</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">face intense <font color="blue">competition</font></font>     for  these <font color="blue">professionals from</font> our <font color="blue"><font color="blue">competitor</font>s</font>, our customers and other     <font color="blue">companies throughout</font> our industry</td>
    </tr>
    <tr>
      <td>We do not <font color="blue">generally enter into <font color="blue">employment</font></font>     <font color="blue">agreement</font>s requiring these employees to continue their <font color="blue">employment</font> for any     period  of  time</td>
    </tr>
    <tr>
      <td>Any <font color="blue">failure on</font> our part to hire, train and retain a     sufficient number of <font color="blue">qualified professionals could seriously damage</font> our     business</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">indebtedness</font> could limit</font> our ability to operate our business, obtain     <font color="blue"><font color="blue">additional</font> financing</font> and pursue other business <font color="blue">opportunities</font></td>
    </tr>
    <tr>
      <td>As  of  <font color="blue">December </font>31, 2005, we had approximately dlra4dtta0 million of     <font color="blue">outstanding <font color="blue">indebtedness</font></font> related to <font color="blue">industrial revenue bonds</font></td>
    </tr>
    <tr>
      <td>At <font color="blue">December </font>31, 2005,                                         10       _________________________________________________________________    [64]Table of <font color="blue">Contents       </font>there was dlra5dtta5 million outstanding under this revolving credit <font color="blue">facility</font>,     which was <font color="blue">paid off on</font> January 3, 2006</td>
    </tr>
    <tr>
      <td>Our <font color="blue">indebtedness</font> could have negative     <font color="blue">consequences</font> for us, including the following:         •  we will need a portion of our <font color="blue">cash flow</font> to pay the principal and     <font color="blue">interest on</font> our <font color="blue">indebtedness</font>, including <font color="blue">indebtedness</font> we may incur in the     future;         •  payments of our <font color="blue">indebtedness</font> will reduce the funds that <font color="blue">would otherwise</font>     be available for our <font color="blue">operations</font> and future business <font color="blue">opportunities</font>;         •  we may have <font color="blue">greater relative debt burdens than</font> our <font color="blue"><font color="blue">competitor</font>s</font>, which     may place us at a <font color="blue">competitive</font> disadvantage;         •  our <font color="blue">debt level may</font> make us more <font color="blue">vulnerable than</font> our <font color="blue"><font color="blue">competitor</font>s</font> to a     downturn in our business or the economy in general; and         •  <font color="blue">there would</font> be a material adverse effect on our business and financial     condition if we are unable to service our <font color="blue">indebtedness</font> or obtain <font color="blue">additional</font>     financing</td>
    </tr>
    <tr>
      <td>We may not have financing for future capital <font color="blue">requirements</font>, which may prevent     <font color="blue">us from addressing gaps</font> in our <font color="blue">product offerings</font> or improving our     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font><font color="blue">historically</font>  our  <font color="blue">cash flow</font> from <font color="blue">operations</font> has been     sufficient to satisfy working capital, capital expenditure and research and     <font color="blue">development</font> <font color="blue">requirements</font>, in the future we may need to incur <font color="blue">additional</font> debt     or <font color="blue">issue equity</font> in order to fund these <font color="blue">requirements</font> as well as to make     <font color="blue">acquisitions</font> and other <font color="blue">investment</font>s</td>
    </tr>
    <tr>
      <td>Our senior credit <font color="blue">facility</font> restricts our     ability to <font color="blue">incur new debt</font></td>
    </tr>
    <tr>
      <td>If we cannot obtain <font color="blue">additional</font> debt or equity     <font color="blue">financing on</font> acceptable terms or if we are limited <font color="blue">with respect</font> to incurring     <font color="blue">additional</font> debt or <font color="blue">issuing equity</font>, we may be unable to <font color="blue">address gaps</font> in our     <font color="blue">product offerings</font> or improve our <font color="blue">technology</font>, <font color="blue">particularly</font> through strategic     <font color="blue">acquisitions</font> or <font color="blue">investment</font>s</td>
    </tr>
    <tr>
      <td>We may need to raise substantial amounts of money to fund a variety of     <font color="blue">future activities integral</font> to the <font color="blue">development</font> of our business, including but     not limited to the following:         •  for research and <font color="blue">development</font> to <font color="blue">successfully</font> develop <font color="blue">additional</font>     products;         •  to file and <font color="blue">prosecute patent <font color="blue"><font color="blue">application</font>s</font></font> and defend and assert patents     to protect our <font color="blue">technology</font>;          •   to retain qualified employees, <font color="blue">particularly</font> in light of intense     <font color="blue">competition</font> for <font color="blue">qualified scientists</font>;          •   to  <font color="blue">manufacture</font>  <font color="blue">additional</font> products ourselves or <font color="blue">through third</font>     parties; and         •  to acquire <font color="blue">new <font color="blue">technologies</font></font>, products or companies</td>
    </tr>
    <tr>
      <td>If we <font color="blue">raise funds through</font> the issuance of debt or equity, any debt     securities or <font color="blue">preferred stock issued will</font> have rights, preferences and     <font color="blue">privileges senior</font> to those of holders of our <font color="blue">common stock</font> in the event of a     <font color="blue">liquidation</font></td>
    </tr>
    <tr>
      <td>The terms of the <font color="blue">debt securities may impose restrictions on</font> our     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">raise funds through</font> the issuance of equity, this issuance     <font color="blue">would dilute</font> the <font color="blue">ownership interest</font> of our existing <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>We expect     to fund future <font color="blue">acquisitions</font> in part by issuing <font color="blue">additional</font> equity</td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to secure and maintain <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> protection</font> for     our products and <font color="blue">technologies</font> could <font color="blue">adversely</font> affect our ability to compete</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends</font> to a <font color="blue">significant</font> degree upon our ability to     develop, maintain and protect <font color="blue">proprietary</font> products and <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We file     patent  <font color="blue"><font color="blue">application</font>s</font>  in  the <font color="blue">United States </font>and <font color="blue">selectively</font> in foreign     countries as part of our strategy to protect our <font color="blue">proprietary</font> products and     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>However, <font color="blue">patents provide only</font> limited protection of our     <font color="blue"><font color="blue">intellectual</font> property</font></td>
    </tr>
    <tr>
      <td>The assertion of <font color="blue">patent protection involves complex</font>     legal and factual <font color="blue">determinations</font> and is <font color="blue">therefore uncertain</font> and expensive</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot provide assurances</font> that patents will be granted <font color="blue">with respect</font> to     any of our pending patent <font color="blue"><font color="blue">application</font>s</font>, that the scope of any of our patents     will be <font color="blue">sufficiently broad</font> to <font color="blue">offer meaningful protection</font>, or that we will     develop <font color="blue">additional</font> <font color="blue">proprietary</font> <font color="blue">technologies</font> that are patentable</td>
    </tr>
    <tr>
      <td>Our issued     patents, or <font color="blue">third party</font> patents that we license, could be <font color="blue">successfully</font>     challenged,                                         11       _________________________________________________________________    [65]Table of <font color="blue">Contents       </font>invalidated or <font color="blue">circumvented</font></td>
    </tr>
    <tr>
      <td>This could result in our <font color="blue">patent rights failing</font>     to create an effective <font color="blue">competitive</font> barrier</td>
    </tr>
    <tr>
      <td>Losing a <font color="blue">significant</font> patent or     failing to get a patent to issue from a pending patent <font color="blue">application</font> that we     consider <font color="blue">significant</font> could have a material adverse effect on our business</td>
    </tr>
    <tr>
      <td>The <font color="blue">laws governing</font> the scope of <font color="blue">patent coverage</font> in the <font color="blue">United States </font>    and abroad continue to evolve, <font color="blue">particularly</font> in the <font color="blue">life sciences</font> area</td>
    </tr>
    <tr>
      <td>The     laws of some <font color="blue">foreign countries may</font> not protect our <font color="blue"><font color="blue">intellectual</font> property</font>     rights to the <font color="blue">same extent as</font> <font color="blue">United States </font>laws</td>
    </tr>
    <tr>
      <td>We hold <font color="blue">patents only</font> in     <font color="blue">selected countries</font></td>
    </tr>
    <tr>
      <td>Therefore, <font color="blue">third parties</font> can make, use and <font color="blue">sell products</font>     covered  by  our  patents  in countries in which we do not have patent     protection</td>
    </tr>
    <tr>
      <td>We give our customers the right to use some of our products for     <font color="blue">research purposes only under certain licenses</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">licenses could</font> be     contested</td>
    </tr>
    <tr>
      <td>Therefore, <font color="blue">no assurances</font> can be given that we would either be     aware of an <font color="blue">unauthorized use</font> or be able to enforce these <font color="blue">license limitations</font>     in a cost-effective manner</td>
    </tr>
    <tr>
      <td>We  attempt  to  protect  our  trade  secrets  <font color="blue">by entering into</font>     <font color="blue">confidential</font>ity <font color="blue">agreement</font>s with employees, consultants and <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>However, these <font color="blue">agreement</font>s might be breached and, if they are, there may not     be an <font color="blue">adequate remedy available</font> to us</td>
    </tr>
    <tr>
      <td>Also, our <font color="blue">trade secrets might become</font>     known  to  a  third  party  through  means other <font color="blue">than by breach</font> of its     <font color="blue">confidential</font>ity <font color="blue">agreement</font>s, or they could be <font color="blue">independently</font> developed by our     <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">trade secrets become known</font>, our business and <font color="blue">competitive</font>     <font color="blue">position could</font> be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>We are currently, and could in the future be, subject to lawsuits,     <font color="blue">arbitrations</font>, and other legal actions, <font color="blue">particularly</font> involving claims for     <font color="blue">infringement</font> of patents and other <font color="blue"><font color="blue">intellectual</font> property</font> rights</td>
    </tr>
    <tr>
      <td>We believe that we have <font color="blue">meritorious defenses against</font> the claims     currently asserted <font color="blue">against us</font> and intend to <font color="blue">defend them vigorously</font></td>
    </tr>
    <tr>
      <td>However,     the outcome of legal actions is <font color="blue">inherently uncertain</font>, and we cannot be sure     that we will prevail in any of these actions</td>
    </tr>
    <tr>
      <td>An adverse determination in     some of our current legal actions, <font color="blue">particularly</font> the <font color="blue">cases described</font> below,     could have a material adverse effect on our business</td>
    </tr>
    <tr>
      <td>Our products are based     on  complex,  rapidly developing <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">products could</font> be     developed <font color="blue">without knowledge</font> of previously filed patent <font color="blue"><font color="blue">application</font>s</font> that     mature  into  patents that cover some aspect of these <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>In     addition,  our belief that our products do not infringe the <font color="blue">technology</font>     <font color="blue">covered by valid</font> and <font color="blue">enforceable patents could</font> be <font color="blue">successfully</font> challenged by     third  parties</td>
    </tr>
    <tr>
      <td>We have from time to time been notified that we may be     <font color="blue">infringing patents</font> and other <font color="blue"><font color="blue">intellectual</font> property</font> rights of others</td>
    </tr>
    <tr>
      <td>Also,     in the course of our business, we may from time to time have access to     <font color="blue">confidential</font> or <font color="blue">proprietary</font> information of <font color="blue">third parties</font>, and these parties     <font color="blue">could bring</font> a claim <font color="blue">against us</font> asserting that we had <font color="blue">misappropriated</font> their     <font color="blue">technologies</font> and had improperly incorporated such <font color="blue">technologies</font> into our     products</td>
    </tr>
    <tr>
      <td>Due  to  these  factors,  there  remains a constant risk of     <font color="blue"><font color="blue">intellectual</font> property</font> <font color="blue">litigation</font> <font color="blue">affecting</font> our business</td>
    </tr>
    <tr>
      <td>We have been made a     party to <font color="blue">litigation</font> involving <font color="blue"><font color="blue">intellectual</font> property</font> matters</td>
    </tr>
    <tr>
      <td>Such actions     currently include the <font color="blue">litigation</font>s described in the <font color="blue">following paragraphs</font>,     some of which, if determined <font color="blue">adversely</font>, could have a material adverse effect     on us</td>
    </tr>
    <tr>
      <td>To avoid or <font color="blue">settle legal</font> claims, it may be <font color="blue">necessary</font> or desirable in     the future to obtain licenses relating to one or more products or relating     to current or future <font color="blue">technologies</font>, and we cannot be assured that we will be     able to obtain these licenses or other <font color="blue">rights on commercially reasonable</font>     terms</td>
    </tr>
    <tr>
      <td>We have <font color="blue">been involved</font> in <font color="blue">significant</font> patent disputes with third     parties, a number of <font color="blue">which remain unresolved</font></td>
    </tr>
    <tr>
      <td>For example, we are involved     in <font color="blue">litigation</font> with <font color="blue"><font color="blue">Invitrogen </font>Corporation </font>regarding patents relating to     <font color="blue">certain enzymes</font> and <font color="blue">competent cell products</font></td>
    </tr>
    <tr>
      <td>In one such <font color="blue">litigation</font>, in     which <font color="blue">Invitrogen </font>alleges damages of up to approximately dlra22dtta0 million, the     <font color="blue"><font color="blue">Federal Circuit Court of Appeals</font> </font>reversed the district court’s prior summary     judgment decision of patent <font color="blue">invalidity</font> due to <font color="blue">public use</font>, affirmed the     district court’s partial summary judgment of <font color="blue">infringement</font>, affirmed the     district  court’s  denial  of  summary  judgment  of <font color="blue">invalidity</font> due to     <font color="blue">indefiniteness</font>, and remanded the case for <font color="blue">further proceedings</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">also involved</font> in <font color="blue">litigation</font> with <font color="blue">Applera Corporation </font>regarding     a  patent  that  <font color="blue">Applera  </font>alleges  is  infringed  by our real-time PCR     <font color="blue">instrumentation</font> and certain related reagents</td>
    </tr>
    <tr>
      <td>In  addition,  we  are  involved  in <font color="blue">litigation</font> with <font color="blue">Third Wave </font>    Technologies regarding patents relating to <font color="blue">certain assays</font> for the <font color="blue">detection</font>     of  <font color="blue">nucleic acids</font></td>
    </tr>
    <tr>
      <td>In a jury trial in August 2005, the <font color="blue">jury returned</font> a     verdict that                                         12       _________________________________________________________________    [66]Table of <font color="blue">Contents       </font>the patents-in-suit were valid and infringed by us, for monetary damages in     the amount of dlra5dtta3 million, and that our <font color="blue">infringement</font> was willful</td>
    </tr>
    <tr>
      <td>Based on     the jury’s verdict, the <font color="blue">district court permanently enjoined us from further</font>     <font color="blue">infringement</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">district court recently awarded</font> <font color="blue">Third Wave </font><font color="blue">treble damages</font>     of dlra15dtta9 million, attorneys’ fees and costs in an amount of dlra4dtta2 million,     and pre-judgment interest of dlra0dtta5 million</td>
    </tr>
    <tr>
      <td>We have posted a dlra21dtta0 million     <font color="blue">civil supersedeas bond</font> to <font color="blue">stay payment</font> of the judgment of the district     court, and filed an appeal to the <font color="blue">Federal Circuit Court of Appeals</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">also involved</font> in <font color="blue">litigation</font> with <font color="blue"><font color="blue">Invitrogen </font>Corporation </font>and     Takara  Bio  regarding one of our patents relating to <font color="blue">polymerase blend</font>     products</td>
    </tr>
    <tr>
      <td>As part of the patent <font color="blue">infringement</font> claims in these matters, we     seek monetary damages, injunctive relief and attorneys’ fees</td>
    </tr>
    <tr>
      <td>As stated     above, the outcome of any such <font color="blue">litigation</font> or appeal is <font color="blue">inherently uncertain</font></td>
    </tr>
  </tbody>
</table>